RxDoctor Payments Data

Sung Park, MD

Neurology · Anaheim, CANPI 1649298084

Payments from drug & device makers

$443in general payments, 2019–2025

Across 19 payments — averaging $23.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$155
  • MDD US Operations, LLC$116
  • Acadia Pharmaceuticals Inc$102
  • Pfizer$70

What the payments were for

  • Food & beverage$443100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)3$155
MDD US Operations, LLC7$116
Acadia Pharmaceuticals Inc5$102
Pfizer4$70

How this compares

$443 in reported general payments places this provider in the 35th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$270,654
Medicare patients
482
Services billed
16,643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BetaseronInterferon Beta-1b15$146,361
Galantamine Hbr1,045$96,477
NamzaricMemantine Hcl/Donepezil Hcl57$47,429
Memantine Hcl1,783$33,304
Rasagiline Mesylate162$28,184
CreonLipase/Protease/Amylase21$27,219
EliquisApixaban28$27,169
LinzessLinaclotide39$25,021
Memantine Hcl ErMemantine Hcl121$21,452
VimpatLacosamide11$12,661
Gabapentin822$10,872
Carbidopa-LevodopaCarbidopa/Levodopa409$9,736
Pregabalin624$9,706
Donepezil Hcl619$8,324
ExelonRivastigmine12$8,097

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieNamzaric, Creon, Linzess$155$99,669117 claims
PfizerEliquis$70$27,16928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,996 neurology providers in California.

Other neurology in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →